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The lipid 12,13-diHOME acts as cold induced lipokine in mice and humans to 
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MAIN TEXT 
INTRODUCTORY PARAGRAPH (200 WORDS MAX) 
Brown adipose tissue (BAT) and beige adipose tissue combust fuels for heat 
production in adult humans, constituting an appealing target for treatment of metabolic 
disorders such as obesity, diabetes, and hyperlipidemia1,2. Cold exposure can improve 
nutrient metabolism and enhance energy expenditure by activating BAT3-5. These 
therapies, however, are time consuming and uncomfortable, increasing the need for 
pharmacological interventions. Recently, lipids called “lipokines” with signaling properties 
promoting insulin sensitivity and glucose tolerance have been identified6-8. As BAT is a 
specialized lipid metabolic tissue linked to systemic metabolic homeostasis, we 
hypothesized that there may be thermogenic lipokines that activate BAT in response to 
cold. Here we show the lipid 12,13-dihydroxy-9Z-octadecenoic acid (12,13-diHOME) is 
an indicator and stimulator of BAT activity that negatively correlates with body mass 
index and insulin sensitivity. Using a global lipidomic analysis, we found 12,13-diHOME 
was increased in the circulation of cold challenged humans and mice and the enzymes 
that produce 12,13-diHOME were uniquely induced in BAT by cold. 12,13-diHOME 
acutely activated BAT fuel uptake and enhanced cold tolerance, resulting in decreased 
serum triglycerides. Mechanistically, 12,13-diHOME increased fatty acid (FA) uptake into 
brown adipocytes by promoting translocation of FA transporters FATP1 and CD36 to the 
cell membrane. In summary, our results identify a novel mechanism of BAT activation 
through a lipokine produced in response to cold. These data suggest novel therapeutic 
pathways for the treatment of metabolic disorders by mimicking cold. 
 
BODY (1500 WORDS MAX) 
Cold exposure activates substrate uptake and utilization in BAT in as little as one 
hour in humans9. We hypothesized that thermogenic lipokines linked to BAT activation 
might increase in subjects exposed to a cold challenge as lipokines can have effects on 
improving metabolism similar to cold exposure10. To test this hypothesis, we used liquid 
chromatography tandem mass spectrometry (LC-MS/MS) to measure the concentrations 
of a panel of 88 lipids with annotated signaling properties in the plasma of human 
volunteers exposed to cold9 (Supplementary Fig. 1a,1b Supplementary Table 1). This 
approach to identify putative lipokines is highly sensitive and covered a broad range of 
oxidized fatty acid metabolites. Notably, 3 species were significantly increased by cold in 
human circulation after 1 hour of cold challenge (p<0.05, Fig. 1a, Supplementary Fig. 2). 
The lipid 12,13-diHOME, however, was the only species that increased in all subjects 
measured (Fig. 1b) and 12,13-diHOME concentration correlated to BAT activity 
measured by radiolabeled glucose uptake (Fig. 1c). BAT activity and mass are both 
decreased with obesity1, so to determine if 12,13-diHOME links to human obesity and its 
related metabolic disorders, we measured 12,13-diHOME in a cohort of 55 lean, 
overweight, and obese human subjects at room temperature. Importantly, we found 
significant negative associations between plasma concentration of 12,13-diHOME and 
body mass index (BMI), insulin resistance (measured by HOMA-IR), fasting plasma 
insulin and glucose concentrations (Fig. 1d-e and Supplementary Fig 3b-c, 3j), although 
the correlation with hemoglobin A1c and c-reactive peptide was not as strong 
(Supplementary Fig. 3d, 3e). Consistent with BMI, circulating triglycerides and leptin 
were also negatively correlated with plasma 12,13-diHOME (Fig. 1f and Supplementary 
Fig. 3f). Notably, circulating triglycerides remained significantly correlated to 12,13-
diHOME after we accounted for BMI as a covariate in a linear model (p=0.0463, 
Supplementary Table 1). Circulating markers of liver function, such as alanine 
transaminase (ALAT) (Fig. 1g), aspartate transaminase (ASAT) (Supplementary Fig. 
3h), and gamma-glutamyl transpeptidase (gGT) (Supplementary Fig. 3i), were inversely 
correlated with 12,13-diHOME concentration and both ALAT and ASAT remained 
significantly correlated when BMI was accounted as a covariate (p=0.0494, p=0.0274 
respectively). Cholesterol, on the other hand, did not correlate with circulating 12,13-
diHOME (Fig. 1h-I and Supplementary Fig. 3g). In this particular cohort of subjects, we 
found that circulating 12,13-diHOME had no association with age, gender or diabetes 
(Supplementary Fig. 3a, 3k-l). . 
To allow in-depth mechanistic studies, we established a cold exposure model 
using mice housed at either 30 °C thermoneutrality (minimal BAT activity) or 4 °C 
(maximal BAT activity) for various durations. Consistent with what was observed in 
humans, exposing mice to 4°C for 1 hour increased circulating 12,13-diHOME (Fig. 2a). 
Of note, treatment of mice with norepinephrine (NE) for 30 minutes, which mimics 
sympathetic activation, also induced 12,13-diHOME production, suggesting that 12,13-
diHOME is a potential product induced by both cold and sympathetic activation. Similar 
to acute cold challenge, one week of cold exposure also induced a pronounced increase 
in circulating 12,13-diHOME in male mice (Fig. 2b). In female mice, 12,13-diHOME was 
not significantly changed in circulation after one week of cold exposure, however, this 
increase did reach statistical significance after exposed to cold for 11 days (Fig. 2b, 
Supplementary Fig. 4a), which may be related to the reported sexual dimorphism of lipid 
profiles in mouse BAT11.  
12,13-diHOME was originally identified in mice as a component of the neutrophil 
oxidative burst,12 but has not been previously linked to cold or BAT biology. Biosynthesis 
of 12,13-diHOME and its isomer 9,10-diHOME begins via formation of 12,13- or 9,10-
epOME epoxides from linoleic acid by Cytochrome P450 (Cyp) oxidases, followed by 
hydrolysis catalyzed by soluble epoxide hydrolases (sEH) to form the diols 12,13-
diHOME and 9,10-diHOME (Fig. 2c). Among the four sEH genes, Ephx1 and Ephx2 are 
the major isoforms expressed in adipose tissue13 and although Ephx2 null mice have 
decreased blood pressure14, thermogenic function has not been reported in Ephx115 or 
Ephx2 knockout mice. We found that acute cold exposure (i.e., 1 hour) induced a nearly 
14-fold increase of Ephx2 in BAT (Fig. 2d). Chronic cold (e.g., 1 week) also increased 
both Ephx1 (Fig. 2e) and Ephx2 (Fig. 2f) expression only in BAT but not other tissues 
where sEH is expressed (Supplementary Fig. 4b). Meta-analysis of publically available 
datasets profiling gene expression in BAT from mice exposed to cold for different 
periods of time also consistently showed increased Ephx expression and differential 
regulation of several Cyp genes that may participate in this pathway16-18 in BAT 
(Supplementary Fig. 4c). We detected a high concentration of 12,13-diHOME in adipose 
tissue (Supplementary Fig 4d), and ex vivo experiments showed that 12,13-diHOME 
secretion from BAT is higher than WAT (Fig. 2g). 
To further investigate whether BAT or WAT could be a source of 12,13-diHOME 
upon cold exposure, we used LC-MS/MS to measure 12,13-diHOME in adipose from 
wild-type and Myf5creBMPr1af/f mice, which display a severe defect in classical BAT 
development and a compensatory browning of sWAT19. Cold exposure increased 12,13-
diHOME concentration in BAT from wild-type mice, yet this effect was severely impaired 
in BAT from the Myf5creBMPr1af/f mice (Fig. 2h). These data strongly suggest that BAT is 
a major source of increased circulating 12,13-diHOME after cold exposure, although 
circulating 12,13-diHOME in Myf5creBMPr1af/f mice is not different from control animals 
(Supplementary Fig. 4a), raising the possibility that beige adipocytes recruited in sWAT 
tissue of the Myf5creBMPr1af/f mice might also be a potential source. Concordant with 
these data, 12,13-diHOME was elevated in sWAT from cold challenged male 
Myf5creBMPr1af/f mice with enhanced beige adipogenesis compared to wild-type mice 
housed in cold for two days, while no effect was observed after 11 days in female mice 
(Supplementary Fig. 4e). Pharmacologic BAT activation using daily treatment with the 
β3-adrenergic agonist CL316,243 for 10 days increased Ephx2 expression in BAT and 
Ephx1 expression in sWAT (Supplementary Fig. 4f, 4g), suggesting that 12,13-diHOME 
can be produced by brown or beige fat in response to β3-adrenergic stimulation. One 
challenge to understanding the flux of 12,13-diHOME in vivo is that this lipid can be both 
consumed in the diet and produced in the body, so further characterization of the 
biosynthetic pathway will require labeling 12,13-diHOME itself and warrants future 
studies. 
 To test our initial hypothesis that putative lipokines induced by cold can facilitate 
increased thermogenesis, we treated mice with either 12,13-diHOME and measured 
core body temperature during an acute cold challenge. To minimize cytotoxic effects, we 
chose to use the dosage of 1 µg/kg with a target concentration of 30-50 nM for in vivo 
administration to mimic the physiologic concentration after cold exposure. This dose is 
based on the measured circulating concentration of 12,13-diHOME at room temperature 
and after cold exposure, and is orders of magnitude lower than the reported 
concentration that causes lung mitochondrial dysfunction20. Importantly, treatment with 
12,13-diHOME protected mice from the decrease in body temperature during cold 
challenge compared to both vehicle-treated mice and mice injected with the precursor 
lipid 12,13-epOME (Fig. 3a). Of note, except for a very transient increase in diastolic 
pressure, 12,13-diHOME had no effect on blood pressure and pulse (Supplementary 
Fig. 5a, 5b, 5c), suggesting that 12,13-diHOME possesses a therapeutic benefit over 
sympathomimetics for BAT activation by avoiding potential side effects21, such as 
tachycardia or hypertension. Consistent with these findings, 12,13-diHOME-treated 
animals displayed increased oxygen consumption and carbon dioxide production in the 
cold (Fig. 3b). These changes result in a decreased respiratory exchange ratio (Fig. 3c), 
indicating increased lipid oxidation and further suggesting the effect of 12,13-diHOME on 
BAT metabolism is mediated, at least in part, through enhanced lipid metabolism.  
To test therapeutic applications of 12,13-diHOME, we treated diet-induced obese 
mice with 12,13-diHOME daily for 2 weeks at 10 µg/kg body weight. Although no effect 
on body weight, glucose tolerance, or circulating non-esterified FA (Supplementary Fig. 
6a, 6b, 6c) were observed at this dose, 12,13-diHOME decreased circulating 
triglycerides (Fig. 3d) and increased expression of lipoprotein lipase (LPL) in BAT, 
suggesting increased hydrolysis of triglycerides22,23 (Supplementary Fig. 6d). These 
results, together with well-supported reports that activated BAT takes up large quantities 
of FA from circulating triglyceride-rich lipoproteins23-27, led us to test the effects of 12,13-
diHOME on lipid uptake in vivo. Since 12,13-diHOME decreased circulating triglycerides 
and the principal source of FA in vivo is in the form of triglycerides packaged into 
lipoproteins, we measured the effect of 12,13-diHOME on the uptake of radiolabeled 
triglycerides delivered by oral gavage (Fig. 3e).  Indeed, mice treated with 12,13-
diHOME exhibited increased BAT specific lipid uptake and improved oral lipid tolerance 
(Supplementary Fig. 6e).  Similarly, 12,13-diHOME increased radiolabeled FA uptake 
(Fig. 3f) and glucose uptake (Supplementary Fig. 6f) specifically into BAT, similar to a 
level achieved by NE stimulation.  
Given the fast and dynamic nature of FA uptake, we sought to monitor 12,13-
diHOME-stimulated fatty acid uptake in real time. We generated transgenic mice 
expressing firefly luciferase specifically in brown adipocytes (UCP1cre+/-Rosa(stop)Luc+/-
). We injected these mice intravenously with FFA-SS-Luc, a fatty acid-luciferin conjugate 
that follows the uptake of natural FA and releases luciferin only after internalization28. In 
this model, luciferase is exclusively expressed in UCP1-expressing adipocytes, so the 
luciferin substrate can only be oxidized in these cells to release light to measure brown 
adipocyte FA uptake (Fig. 3g, Supplementary Video 1). Mice treated with 12,13-diHOME 
had an increased luminescent signal in BAT compared to vehicle-treated animals that 
was both rapid and sustained over the course of the experiment (Fig. 3h, 3i). Taken 
together, these data demonstrate a pro-thermogenic effect of 12,13-diHOME that is 
linked to acute BAT-specific FA uptake. 
To identify potential cell autonomous mechanisms for increased FA uptake in 
BAT, we tested the effects of 12,13-diHOME on brown adipocytes constitutively 
expressing luciferase in vitro. In agreement with experiments in vivo, FFA-SS-Luc 
uptake in vitro was also increased (Fig. 4a, Supplementary Video 2), while no additive 
effect of NE treatment was observed (data not shown), suggesting 12,13-diHOME might 
act downstream of NE. Similarly, 12,13-diHOME markedly increased radiolabeled FA 
uptake in brown adipocytes with an increase FA oxidation that did not reach statistical 
significance (Fig. 4b, 4c). As a result of consuming the FA fuel, basal respiration was 
increased in 12,13-diHOME treated brown adipocytes (Fig. 4d), but there was no effect 
on maximal respiratory capacity or uncoupling Together with the in vivo data (Fig. 3b, 
3c), these findings indicates that the effect of 12,13-diHOME was primarily to increase 
metabolic flux and fuel consumption. In adipocytes, FA uptake is mediated in part by a 
diverse family of fatty acid transport proteins including CD36 and FATP1, both of which 
are hormone-sensitive FA transporters26,29 required for non-shivering thermogenesis in 
mice30,31. Membrane translocation of both the low glycosylation form of CD3626 and 
oligomeric FATP132 are robustly induced by 12,13-diHOME, consistent with increased 
fatty acid uptake (Fig. 4e, 4f, 4g, Supplementary Fig. 7). Fractionation of cellular 
compartments was confirmed using Tubulin as a marker of cytosol and Cadherin to mark 
the membrane. 
Taken together, these results lead us to propose a model (Fig. 4h), wherein cold 
exposure activates production of 12,13-diHOME in BAT tissue by increasing lipolysis to 
provide substrates for sEH and increasing sEH gene expression, ultimately leading to 
increased circulating 12,13-diHOME. 12,13-diHOME acts, at least in part, via an 
autocrine/paracrine mechanism to activate fatty acid transporter translocation in brown 
adipocytes leading to increased FA uptake and triglyceride clearance, facilitating 
thermogenesis by providing fuel. Chronic cold exposure further increases gene 
expression of sEH, specifically in brown or beige adipocytes, to increase biosynthesis of 
12,13-diHOME. Notably, even metabolically inert fatty acids are known to directly 
activate UCP133, and the direct effects of 12,13-diHOME on UCP1-mediated uncoupling 
require further investigation. Our in vivo experiments, however, supported a direct effect 
of 12,13-diHOME on FA uptake.  
Based on our model, 12,13-diHOME facilitates BAT thermogenic activity by 
selectively promoting fuel uptake, suggesting potential applications for treating 
hyperlipidemia. Indeed, acute 12,13-diHOME treatment protected mice from cold 
challenge, and chronic treatment (i.e., one week) of obese mice with 12,13-diHOME 
resulted in a reduction of circulating triglyceride without alteration of body weight. These 
data point out a complex fuel consumption and refueling process that impact energy 
balance during cold exposure and presumably upon 12,13-diHOME treatment. In cold 
conditions, fatty acids in brown adipocytes serve as both fuels to be oxidized for 
thermoregulation, as well as substrates for biosynthesis of 12,13-diHOME. Since 12,13-
diHOME activates fatty acid uptake, consumption of cellular fuel is coupled to a potent 
and specific refueling signal. By identifying this mechanism of BAT specific lipid 
utilization, it may be possible to unlock the maximum therapeutic potential of brown fat in 
humans.  
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MAIN FIGURE LEGENDS 
Figure 1. Discovery of 12,13-diHOME, a cold-induced lipokine linked to BAT activation. 
(a) Volcano plot of 88 lipids comparing the fold induction after cold challenge to the p 
value (paired t-test). The dashed line indicates a p value of 0.05. 12,13-diHOME is 
highlighted in red. n=9 individual subjects. (b) Individual plasma concentration of 12,13-
diHOME before and after cold challenge. The p-value for a paired t-test is shown. (c) 
Plasma 12,13-diHOME concentration plotted with BAT specific activity as measured by 
positron emission tomography (PET) scan of radiolabeled fluorodeoxyglucose. R is the 
Spearman correlation between 12,13-diHOME and BAT activity. (d-i) Circulating 12,13-
diHOME concentration plotted against body mass index (BMI) (d), HOMA-IR (e), 
circulating triglycerides (f), circulating alanine transaminase (ALAT) (g), circulating HDL-
cholesterol (h), and LDL-cholesterol (i). In each panel, R is the Spearman correlation 
between 12,13-diHOME and each circulating parameter. In each panel males are shown 
in blue while females are shown in pink. N=55 individual subjects (13M/42F). The p 
value shown was calculated using algorithm AS 89.  
 
Figure 2. The biosynthetic pathway of 12,13-diHOME is selectively increased in BAT 
with cold in mice. (a) Serum 12,13-diHOME concentration in control mice compared to 
mice treated with Norepinephrine (NE) for 30 minutes and mice exposed to 4°C cold for 
1 hour. Data are means +/- s.e.m.; n= 6 control mice, 7 NE treated, 7 cold exposed. 
*p<0.05, *p<0.005 by t-test. (b) Serum concentration of 12,13-diHOME in male and 
female mice after a 7 day cold challenge vs. mice housed at thermoneutrality. Data are 
means +/- s.e.m.; n= 6 mice per group; *p<0.05 by t-test. (c) Biosynthetic pathway of 
12,13-diHOME production. (d) Ephx1 and Ephx2 mRNA expression measured by qPCR 
in BAT from control mice vs. mice exposed to 4°C cold for 1 hour. Data are means +/- 
s.e.m.; n= 6 control mice, 7 cold exposed. *p<0.05 by t-test. (e) Ephx1 gene expression 
measured by qPCR in BAT, sWAT, and eWAT from mice housed at thermoneutrality or 
cold for 7 days. Data are presented as normalized means ± s.e.m.; n=4 per group; 
*p<0.05 by t-test. (f) Ephx2 gene expression measured by qPCR in BAT, sWAT, and 
eWAT of mice housed at either thermoneutrality or cold for 7 days. Data are presented 
as normalized means ± s.e.m.; n=4 per group; *p<0.05 by t-test. (g) 12,13-diHOME 
concentration in media from BAT and sWAT cultured ex vivo for 1 hour normalized to 
tissue weight. Data are means +/- s.e.m.; n= 6 mice; *p<0.05 by t-test. (h) 12,13-
diHOME concentrations in BAT from wild type and Myf5creBMPr1af/f mice housed at cold 
or thermoneutrality for 2 or 11 days. Data are plotted as the normalized means ± s.e.m.; 
n=5 WT thermoneutral males, 5 WT cold males, 4 Myf5creBMPr1af/f thermoneutral males, 
5 Myf5creBMPr1af/f cold males, 3 WT thermoneutral females, 6 WT cold females, 4 
Myf5creBMPr1af/f thermoneutral females, 6 Myf5creBMPr1af/f cold females; *p<0.05 by t-
test. 
 
Figure 3. 12,13-diHOME enhances cold tolerance and facilitate fatty acid uptake into 
BAT. (a) Body temperature in mice cold challenged at 4°C for 90 min after pretreatment 
with 12,13-diHOME, 12,13-epOME or vehicle. Data are means ± s.e.m.; n=5 per group; 
*p<0.05 12,13-diHOME vs. Vehicle by ANOVA with post-hoc Bonferroni test. (b and c) 
Total V(O2) consumed and V(CO2) produced (b) and average respiratory exchange ratio 
(R.E.R., c) measurements measured by CLAMS for 1 h at cold (4°C) in mice acutely 
treated with 12,13-diHOME or vehicle. (d) Serum triglycerides in mice fed HFD and 
treated with 12,13-diHOME or vehicle for 2 weeks. Data are means +/- s.e.m.; n=6 
treated vs. 5 controls; *p<0.05 by t-test. (e) Radioactivity per 10 mg of liver, 
gastrocnemius muscle (Gastroc), soleus muscle, heart, BAT, sWAT and epididymal 
white adipose tissue (eWAT) from mice treated with vehicle or 12,13-diHOME and then 
given an oral bolus of 3H-labeled triglyceride. Data are means ± s.e.m.; n=6 per group; 
*p<0.05 by t-test. (f) Radioactivity per 10 mg of tissues from mice treated with vehicle, 
Norepinephrine (NE) or 12,13-diHOME and then given a bolus of 3H-labeled oleate. Data 
are means ± s.e.m.; n=8 per group; *p<0.05 12,13-diHOME vs. Vehicle by ANOVA with 
post-hoc Bonferroni test. (g) Representative images of luciferase activity in UCP1cre+/-
Rosa(stop)Luc+/- injected intravenously with luciferin-conjugated fatty acid and 12,13-
diHOME or vehicle. Data are representative images at 0, 10 and 55 min. (h) 
Quantification of luciferase activity in (g). (i) Total luciferase counts from 6 individual 
experiments were averaged plotted as the normalized means ± s.e.m.; n=6 per group; 
*p<0.05 12,13-diHOME vs. vehicle by t-test.  
  
Figure 4. 12,13-diHOME promotes fatty acid uptake in vitro by activating the 
translocation and oligomerization of FA transporters. (a) Fatty acid uptake in mature 
brown adipocytes constitutively expressing firefly luciferase that were pretreated with 
either 12,13-diHOME or vehicle measured by luciferase activity using 10 µM FFA-SS-
Luc. Data are plotted as the normalized means ± s.e.m.; n=6 wells per group; *p<0.05 
12,13-diHOME vs. vehicle by ANOVA with post-hoc Bonferroni test. (b) Radiolabeled 14C 
palmitic acid uptake in mature brown adipocytes pretreated for 15 minutes with either 
12,13-diHOME or vehicle. The data was normalized by protein content. Data are 
presented as means ± s.e.m.; n=10-11 wells per group; *p<0.05 12,13-diHOME vs. 
vehicle by t-test. (c) Radiolabeled 14C palmitic acid oxidation in mature brown adipocytes 
pretreated with either 12,13-diHOME or vehicle. The data was normalized by protein 
content. Data are presented as means ± s.e.m.; n=10-11 wells per group; p value is 
shown for 12,13-diHOME vs. vehicle by t-test. (d) Basal respiration of mature brown 
adipocytes treated with either 12,13-diHOME or vehicle. The data was normalized by 
protein content. Data are presented as means ± s.e.m.; n=10-11 wells per group; 
*p<0.05 12,13-diHOME vs. vehicle by t-test. (e) Western blot analysis of membrane and 
cytosol fractions of differentiated WT-1 brown adipocytes treated with 12,13-diHOME or 
vehicle. Data are presented as a representative image; n=3 separate experiments. (f) 
The upper band corresponding to the oligomer form of FATP1 was measured by 
densitometry from immunoblots of three independent experiments. Data are presented 
as means ± s.e.m.; n=3 separate experiments; *p<0.05 12,13-diHOME vs. vehicle by 1-
way ANOVA. (g) Densitometry of the low glycosylation form of CD36 from immunoblots 
of three independent experiments. Data are presented as means ± s.e.m.; n=3 separate 
experiments; *p<0.05 12,13-diHOME vs. vehicle by 1-way ANOVA. (h) Proposed model 
of 12,13-diHOME biosynthesis and action in cold activated BAT.  
 
ONLINE METHODS 
General experimental approaches 
No samples, mice, human subjects or data points were excluded from the 
reported analyses. Samples were not randomized to experimental groups. Analyses 
were not performed in a blinded fashion except as noted below. 
 
Human Subjects 
Human plasma was acquired from a previously performed cold exposure 
experiment approved by the Human Studies Institutional Review Boards of Beth Israel 
Deaconess Medical Center9. All subjects gave written informed consent before taking 
part in the study. Briefly, 9 healthy volunteers participated in 3 separate, independent 
study visits conducted in random order based on a Latin Square design. The night 
before the study day, the subjects were admitted to the clinical research center and 
began fasting from 12:00 AM onward. Room temperature was maintained above 23 °C 
throughout the stay in the clinical research center. Upon waking the next morning, the 
volunteers put on a standard hospital scrub suit. Depending on the study day, one of 
three stimuli was given: a single intramuscular dose of ephedrine 1 mg/kg; an equal 
volume of saline; or the volunteer was transported to a room set to 20 °C and donned a 
surgeon’s cooling vest (Polar Products) with the water temperature set to 14 °C that was 
monitored by a digital thermometer (Fisher Scientific). Sixty minutes after the injection of 
ephedrine, saline, or the initiation of cold exposure, blood was drawn for measurement 
of lipid levels, and then an intravenous bolus of 440 MBq (12 mCi) of 18F-FDG was 
administered. 60 min after the 18F-FDG injection, images were acquired using a 
Discovery LS multidetector helical PET-CT scanner (GE Medical Systems). BAT mass 
and activity were both quantified using the PET-CT Viewer shareware.  
For the second cohort of human subjects, 55 individuals were selected from the 
Leipzig biobank (42 women, 13 men) to represent a wide range of body mass index 
(BMI: 17.5 – 75.4 kg/m²), categories of lean (BMI<25kg/m²; n=15; 4 M/11 F), overweight 
(BMI 25.1-29.9kg/m²; n=13; 4 M/9 F) or obese (BMI>30kg/m²; n=27; 5 M/22 F) and 
glucose metabolism parameters (fasting plasma glucose 3.9 – 13.4 mmol/l; fasting 
plasma insulin 3.8 – 451 pmol/l, HOMA-IR: 0.1 - 25). In the subgroup of lean, all 
individuals were normal glucose tolerant (NGT), whereas in the overweight subgroup, 10 
individuals with NGT and 3 with type 2 diabetes (T2D) and in the obese group 20 NGT 
and 7 T2D subjects were included. Phenotyping, definition of NGT and T2D, as well as 
analyses of serum/plasma parameters (fasting plasma insulin (FPI), fasting plasma 
glucose (FPG), hemoglobin A1c (HbA1c), C-reactive protein (CrP), leptin, total 
cholesterol, aspartate transaminase (ASAT), and gamma-glutamyl transpeptidase (gGT) 
serum concentrations) were performed as described previously35. The collection of 
human biomaterial, serum analyses and phenotyping were approved by ethics 
committee of the University of Leipzig (approval numbers: 159-12-21052012 and 017-
12-23012012) and all subjects gave written informed consent before taking part in the 
study. 
 
Lipidomic profiling and 12,13-diHOME quantification 
All lipid standards were purchased from Cayman Chemical Company, Avanti 
Polar Lipids, or Santa Cruz Biotechnology, Inc. C18SPE cartridges were purchased from 
Biotage. All solvents are of HPLC or LC-MS/MS grade and were acquired from Sigma-
Aldrich, Fisher Scientific, or VWR International. Tissue samples were homogenized in 
0.1x PBS in Omni homogenizing tubes with ceramic beads at 4oC. Aliquots of 100 µL 
serum or 1mg protein of homogenized tissue (measured by BCA) were taken, depending 
on the experiment. A mixture of deuterium-labeled internal standards was added to each 
aliquot, followed by 3x volume of sample of cold methanol (MeOH). Samples were 
vortexed for 5 min and stored at −20 °C overnight. Cold samples were centrifuged at 
14,000g for 10 min, and the supernatant was then transferred to a new tube and 3 mL of 
acidified H2O (pH 3.5) was added to each sample prior to C18 SPE and performed as 
previously described36. The methyl formate fractions were collected, dried under 
nitrogen, and reconstituted in 50 µL MeOH:H2O (1:1, by volume). Samples were 
transferred to 0.5 mL tubes and centrifuged at 20,000g at 4 °C for 10 min. Thirty-five 
microliters of supernatant was transferred to LC–MS/MS vials for analysis using the 
BERG LC–MS/MS mediator lipidomics platform. Separation of signaling lipids was 
performed on an Ekspert MicroLC 200 system (Eksigent Technologies) with a Synergi™ 
Fusion-RP capillary C18 column (150 × 0.5 mm, 4 µm; Phenomenex Inc.) heated to 
40°C. A sample volume of 10 µL was injected at a flow rate of 20 µL/min. Lipids were 
separated using mobile phases A (100 % H2O, 0.1 % acetic acid) and B (100 % MeOH, 
0.1 % acetic acid) with a gradient starting at 60% B for 0.5 min, steadily increasing to 
80% B by 5 min, reaching 95% B by 9 min, holding for 1 min, and then decreasing to 
60% B by 12 min. MS analysis was performed on a SCIEX TripleTOF® 5600+ system 
using the HR-MRM strategy consisting of a TOF MS experiment looped with multiple 
MS/MS experiments. MS spectra were acquired in high-resolution mode (>30,000) using 
a 100-ms accumulation time per spectrum. Full-scan MS/MS was acquired in high 
sensitivity mode, with an accumulation time optimized per cycle. Collision energy was 
set using rolling collision energy with a spread of 15V. The identity of a component was 
confirmed using PeakView® software (SCIEX), and quantification was performed using 
MultiQuant™ software (SCIEX). The quantification of 12,13-diHOME was performed 
against a standard calibration curve built with 5 points ranging from 0.01pg/µL to 
100pg/µL. Obtained values were corrected with the corresponding internal standard d4-
9,10-diHOME. All measurements were performed in a blinded fashion. 
 
Mice and treatments 
All animal procedures were approved by the Institutional Animal Use and Care 
Committee at Joslin Diabetes Center and Harvard T.H. Chan School of Public Health. 
The experiments were not randomized. No statistical method was used to predetermine 
animal's sample size. For the cold exposure experiments, radiolabeled FA uptake 
experiment, and diet-induced obesity experiment, 12 week old male C57BL/6J mice 
(Stock no. 000664) were purchased from The Jackson Laboratory. For acute BAT 
activation, mice were either sacrificed as control animals, treated with NE for 30 minutes, 
or placed at 4°C for 1 hour, then sacrificed for serum and tissue collection. In chronic 
cold exposures, transgenic mice carrying floxed alleles for the BMP receptor 1A were 
used to generate conditional gene deletions mouse models by intercrossing with Myf5-
driven cre recombinase and compared to cre-negative littermate controls as described 
previously19. In addition to C57BL/6J mice, these transgenic animals were used for all 
chronic cold exposure experiments, with mice 10-18 weeks of age housed in a 
temperature controlled diurnal incubator (Caron Products & Services Inc.) at either 4°C 
(cold) or 30°C (thermoneutrality) on a 12 hour light/dark cycle. In all experiments, 
interscapular BAT, inguinal sWAT, and serum were dissected after sacrifice. 
For ex vivo tissue incubation experiments, interscapular BAT and inguinal sWAT 
were dissected from 12 week old male C57BL/6J mice and incubated at 37°C in Krebs 
solution for 1 hour, after which the tissue was discarded and LC-MS/MS was performed 
on the conditioned Krebs solution. 
For cold tolerance assay, mice were injected retro-orbitally with 1 µg/kg body 
weight 12,13-diHOME in 0.1% w/v BSA in PBS or vehicle, then immediately placed in a 
cold room maintained at 4°C and body core temperature was determined by rectal probe 
measurements. Mice injected retro-orbitally were also used to measure blood pressure 
and pulse with the tail cuff method (Hatteras Instruments). 
For in vivo triglyceride organ uptake studies, mice were orally gavaged with 10 
mL/kg olive oil (Sigma) containing [9,10-3H(N)]-triolein (PerkinElmer, 0.3 mCi/kg) 15 
minutes after treatment with either vehicle, 1 µg/kg body weight 12,13-diHOME in 0.1% 
BSA PBS. Similarly, an oleate/3H-oleate tracer mix was complexed to fatty acid-free 
BSA26 and injected into the tail vein of wild type C57BL/6J mice 15 minutes after 
treatment with either vehicle, 1 µg/kg body weight 12,13-diHOME in 0.1% BSA PBS or 
NE.  Glucose uptake studies were also performed by injection into the tail vein with 2-
desoxy-D-[14C] -glucose (PerkinElmer, 0.025 mCi per kg) in PBS 15 minutes after 
treatment with either vehicle, 1 µg/kg body weight 12,13-diHOME in 0.1% BSA PBS or 
NE. In all assays, organs were harvested after 15 minutes of radiotracer uptake under 
terminal anesthesia and systemic perfusion with PBS-heparin (10 U/ml) via the left heart 
ventricle. Tissues were homogenized by using Solvable (PerkinElmer) and 
disintegrations per minute per organ data were calculated by scintillation counting. 
For in vivo bioluminescent fatty acid uptake experiments, UCP1cre+/- mice (Stock 
no. 024670) were bred with Rosa(stop)Luc+/+ (Stock no. 005125), both obtained from 
The Jackson Laboratory. Male offspring carrying the UCP1-cre allele were injected retro-
orbitally with 1 ug/kg body weight 12,13-diHOME in 0.1% BSA PBS or vehicle, and all 
mice were co-injected with 2 µm FFA-SS-Luc (Intrace Medical). Mice were anesthetized 
with isofluorane and imaged using the IVIS Spectrum CT using sequential 30 s 
exposures for 1 hour. Data was analyzed using Living Image Software and movies were 
assembled from individual images using ImageJ.  
For CLAMS studies, mice were injected intravenously with 1 µg/kg body weight 
12,13-diHOME in 0.1% BSA PBS or vehicle and then monitored using the CLAMS 
system in cold conditions (4°C) for 1 hour. Respiratory exchange ratio (R.E.R.) was 
calculated as the ratio of total carbon dioxide produced to total oxygen consumed. 
For the experiments with daily injections of 12,13-diHOME, mice were fed with a 
high-fat diet containing 60 kcal% fat (Research Diets Stock no. D12492) for 16 weeks 
prior to treatment and during the course of the experiment. Mice were first injected 
intraperitoneally daily with 1ug/kg body weight,13-diHOME in 0.1% BSA w/v in PBS or 
vehicle and body for one week, then injected every day with 10ug/kg body weight two 
weeks. For all experiments, serum was collected and triglycerides were measured using 
a standard enzymatic assay (ZenBiosystems). Non-esterified FA were also measured 
with a colorimetric assay (Wako Chemicals USA). High-density and low-density 
lipoprotein fractions were isolated and cholesterol was measured with a colorimetric 
assay (Abcam). All mice were allowed ad libitum access to water and food. 
 
mRNA Expression 
Total RNA was extracted from tissue with Trizol and purified using a spin column 
kit (Zymo Research). RNA (500 ng-1 µg) was reverse transcribed with a high-capacity 
complementary DNA (cDNA) reverse transcription kit (Applied Biosystems). Real-time 
PCR was performed in mouse tissues starting with 10 ng of cDNA and forward and 
reverse oligonucleotide primers (300 nM each) in a final volume of 10 µl with SYBR 
green PCR Master Mix (Roche). Fluorescence was determined and analyzed in an ABI 
Prism 7900 sequence detection system (Applied Biosystems). Acidic ribosomal 
phosphoprotein P0 (ARBP) expression was used to normalize gene expression. Real 
time PCR primer sequences are listed in Supplementary Table 3.  
 
In vitro lipid assays 
Stromal vascular cells were isolated from interscapular brown adipose tissue 
dissected from TgLuc mice (Stock no. 008450) obtained from The Jackson Laboratory. 
Cells were immortalized and differentiated into adipocytes in vitro according to the WT-1 
protocol34. After 1 hour of serum starvation, mature adipocytes were treated with 1 µM 
12,13-diHOME or methyl acetate vehicle in 0.1% w/v BSA in PBS for 15 minutes. After 
this treatment, cells were incubated with 10 µm FFA-SS-Luc (Intrace Medical) and 
imaged using the IVIS Spectrum CT using sequential 30 s exposures for 1 hour. Data 
was analyzed using Living Image Software and movies were assembled from individual 
images using ImageJ. All cultures were confirmed to be Mycoplasma free. 
FA uptake and oxidation were determined by measuring both 14C-labeled palmitic 
acid uptake and conversion of 14C-labeled palmitic acid into CO2. WT-1 brown 
preadipocytes were differentiated according to a standard adipogenic differentiation 
protocol for 9 days before cells were serum starved for 1 hour. Cells were treated with 1 
µM 12,13-diHOME or methyl acetate vehicle in 0.1% w/v BSA in PBS for 15 minutes 
before the culture medium was removed, and cells were incubated with DMEM/H 
containing 4% FA-free BSA w/v in PBS, 0.5 mM palmitic acid, and 0.2 µCi/mL [1-14C]-
palmitic acid (PerkinElmer Life and Analytical Science, Waltham, MA) for 1 h. The 
incubation medium was transferred to a vial containing 1M acetic acid, capped quickly, 
and allowed to incubate for 1 h for CO2 gas to be released. 14 The CO2 released was 
absorbed by hyamine hydroxide, and activity was counted. FA oxidation was calculated 
from CO2 generated. To measure fatty acid uptake, cells were rinsed twice with PBS and 
lysed after incubation with [1-14C]-palmitic acid. Lipids were extracted using a 
chloroform-methanol mixture (2:1), and 14C-counts were determined in the organic 
phase. Protein concentrations were determined by using the Pierce BCA kit (Life 
Technologies) according to instructions, and FA uptake (14C lipids in the cells) and 
oxidation (14CO2 generated) were normalized to protein content. All cells were confirmed 
to be Mycoplasma free. 
 
Seahorse Bioanalyzer 
WT-1 brown preadipocytes were seeded onto gelatin coated Seahorse Plates 
and differentiated according to standard protocols. Cells were starved for 1 h, then 
treated for 15 min with 1 µM 12,13-diHOME or methyl acetate vehicle. The oxygen 
consumption rates (OCR) were monitored in 200 µM palmitic acid plus 100 µM albumin 
in a Seahorse XF24 instrument using the standard protocol of 3 min mix, 2 min wait, and 
3 min measure. For the normalization of respiration to protein content, cells were lysed 
in RIPA buffer and protein concentration was measured using the Pierce BCA kit (Life 
Technologies). 
 
Membrane Fractionation 
WT-1 brown preadipocytes were differentiated according to a standard 
adipogenic differentiation protocol for 9 days before cells were serum starved for 1 hour. 
Cells were treated with 1 µM 12,13-diHOME or methyl acetate vehicle in 0.1% BSA w/v 
in PBS for 15 minutes before cells were scraped from tissue culture plates into 
homogenization buffer and membranes were separated according to previously 
published protocols37. Protein lysates were stored at -20°C until further use. Protein 
concentrations were determined by using the Pierce BCA kit (Life Technologies) 
according to instructions. For immunoblots, lysates were diluted into Laemmli buffer and 
boiled, then loaded onto 10 % Tris gels for SDS-PAGE. After complete separation of the 
proteins, these were transferred on a PVDF membrane (Amersham Biosciences), 
blocked in western blocking buffer (Roche) and primary antibodies (Antibody Table) 
were applied in blocking buffer over night at 4 °C. After washing 4 x for 15 min with TBS-
T, secondary antibodies were applied for 1 h in blocking buffer. Membranes were 
washed again 3 x times for 15 min in TBS-T and developed using chemiluminescence 
(ThermoFisher). After scanning films, densitometry was analyzed using ImageJ 
software. All antibodies are listed in Supplementary Table 4. 
 
Statistics 
No statistical method was used to predetermine sample size. All experiments were not 
blinded. All statistics were calculated using Microsoft Excel, Graphpad Prism and 
RStudio using LIMMA package. In all cases, we assumed equal variance.  For 
consistency, the Spearman correlation coefficient is shown however all Pearson and 
Kendall coefficients reached similar levels of significance. For all correlation coefficients, 
p value was calculated using algorithm AS 8938.   	  SUPPLEMENTARY	  REFERENCES	  (METHODS)	  34.	   Tseng,	  Y.H.,	  Kriauciunas,	  K.M.,	  Kokkotou,	  E.	  &	  Kahn,	  C.R.	  Differential	  roles	  of	  insulin	  receptor	  substrates	  in	  brown	  adipocyte	  differentiation.	  Mol.	  Cell	  Biol	  
24,	  1918-­‐1929	  (2004).	  35.	   Kloting,	  N.,	  et	  al.	  Insulin-­‐sensitive	  obesity.	  Am	  J	  Physiol	  Endocrinol	  Metab	  299,	  E506-­‐515	  (2010).	  36.	   Powell,	  W.S.	  Extraction	  of	  eicosanoids	  from	  biological	  fluids,	  cells,	  and	  tissues.	  Methods	  Mol	  Biol	  120,	  11-­‐24	  (1999).	  37.	   Nishiumi,	  S.	  &	  Ashida,	  H.	  Rapid	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  of	  a	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Supplementary Figure 1 
Annotation of lipid species profiled by LC-/MS in human and mouse serum and mouse 
adipose tissues. (a) Dendrogram of all lipids included in the initial screen according to 
their original fatty acid and enzymatic pathway. (b) For all lipid species measured by LC-
MS/MS annotation of, whether the lipid was pro- or anti-inflammatory.  
 
Supplementary Figure 2 
Lipid species changed by a one-hour cold challenge. The increase in abundance of 
three lipid species reached a nominal p value of 0.05 after cold exposure. The two 
species with lower significance were only detectable after cold exposure. 
 
Supplementary Figure 3 
Anthropometric correlates of 12,13-diHOME. (a-i) Circulating 12,13-diHOME 
concentration plotted against age (a), fasting plasma insulin (FPI) (b), fasting plasma 
glucose (FPG) (c), hemoglobin A1c (HbA1c) (d), C-reactive protein (CrP) (e), circulating 
leptin (f), circulating total cholesterol (g), circulating aspartate transaminase (ASAT) (h), 
and circulating gamma-glutamyl transpeptidase (gGT) (i). In each panel, R is the 
Spearman correlation coefficient and males are shown in blue while females are shown 
in pink. N=55 individual subjects (13 M/42 F). (j) Circulating 12,13-diHOME in each body 
mass index (BMI) category. Data are presented as normalized means ± s.e.m.; n=15 
lean, 13 overweight and 27 obese subjects. (k) Circulating 12,13-diHOME in each BMI 
category of males and females. Data are presented as normalized means ± s.e.m.; n=15 
lean (4 M/11 F), 13 overweight (4 M/9 F) and 27 obese subjects (5 M/22 F); *p<0.05 by 
t-test. (l) Circulating 12,13-diHOME in each BMI category of subjects with normal 
glucose tolerance (NGT) or Type 2 diabetes (T2D). Data are presented as normalized 
means ± s.e.m.; n=15 lean, 13 overweight (10 NGT/3 T2D) and 27 obese subjects (20 
NGT/7 T2D).  
 
Supplementary Figure 4 
12,13-biosynthesis in cold activated adipose tissue. (a) 12,13-diHOME concentrations 
measured by LC-MS/MS in serum from wild type and Myf5creBMPr1af/f mice housed at 
cold or thermoneutral for 2 or 11 days. Data are plotted as the normalized means ± 
s.e.m.; n=5 WT thermoneutral males, 5 WT cold males, 4 Myf5creBMPr1af/f thermoneutral 
males, 5 Myf5creBMPr1af/f cold males, 3 WT thermoneutral females, 2 WT cold females, 
4 Myf5creBMPr1af/f thermoneutral females, 1 Myf5creBMPr1af/f cold female; *p<0.05 by t-
test. (b) Ephx family gene expression measured by qPCR in different tissues from mice 
housed at cold or thermoneutrality for 7 days. Data are plotted as the means normalized 
to thermoneutrality ± s.e.m.; n=8 per group; *p<0.05 by t-test. (c) Meta-analysis of 4 
publically available BAT gene expression datasets from mice exposed to cold for 
different lengths of time for genes in the 12,13-diHOME biosynthetic pathway. The 
induction by cold of each gene after cold exposure is shown by increased fold change on 
the y axis. (d) 12,13-diHOME concentrations measured in different mouse tissues. Data 
are means +/- s.e.m.; n= 8 mice; *p<0.05, **p<0.005 , ***p<0.0005 by t-test. (e) 12,13-
diHOME concentrations measured by LC-MS/MS in sWAT from wild type and 
Myf5creBMPr1af/f mice housed at cold or thermoneutral for 2 or 11 days. Data are plotted 
as the normalized means ± s.e.m.; n=5 WT thermoneutral males, 5 WT cold males, 4 
Myf5creBMPr1af/f thermoneutral males, 5 Myf5creBMPr1af/f cold males, 3 WT 
thermoneutral females, 2 WT cold females, 4 Myf5creBMPr1af/f thermoneutral females, 1 
Myf5creBMPr1af/f cold female; *p<0.05 by t-test. (f) Ephx1 gene expression measured by 
qPCR in BAT and sWAT from mice treated daily with 1 mg/kg body weight CL316,243 
intraperitoneally for 10 days. Data are presented as normalized means ± s.e.m.; n=6 per 
group; *p<0.05 by t-test. (g) Ephx2 gene expression measured by qPCR in BAT and 
sWAT from mice treated daily with 1 mg/kg body weight CL 316,243 intraperitoneally for 
10 days. Data are presented as normalized means ± s.e.m.; n=6 per group; *p<0.05 by 
t-test. 
 
Supplementary Figure 5 
Physiologic effects of acute 12,13-diHOME treatment in mice. (a) Pulse measured in the 
tail after pretreatment with 12,13-diHOME or vehicle. Data are means ± s.e.m.; n=6 per 
group. (b) Systolic pressure measured in the tail vein after pretreatment with 12,13-
diHOME or vehicle. Data are means ± s.e.m.; n=6 per group. (c) Diastolic pressure 
measured in the tail after pretreatment with 12,13-diHOME or vehicle. Data are means ± 
s.e.m.; n=6 per group.  
 
Supplementary Figure 6 
Physiologic effects of daily 12,13-diHOME injections. (a) Body weights over 7 day 
course of daily injection treatment. Data are means +/- s.e.m.; n=6 treated vs. 5 controls. 
(b) Glucose tolerance test of a separate cohort of diet-induced obesity mice treated 
every other day for 2 weeks with either 12,13-diHOME or vehicle. Data are means +/- 
s.e.m.; n=5 per group. (c) Serum non-esterified free fatty acids (FFA) of mice treated 
daily for one week with either 12,13-diHOME or vehicle. Data are means +/- s.e.m.; n=6 
treated vs. 5 controls. (d) mRNA expression measured by qPCR of UCP1 and LPL in 
tissue from mice treated every other day for two weeks with either 12,13-diHOME or 
vehicle. Data are means +/- s.e.m.; n=6 treated per group; *p<0.05 by t-test. (e) Oral 
lipid tolerance test showing serum triglyceride concentration from mice treated with 
vehicle or 12,13-diHOME and then given an oral bolus of triglyceride. Data are means ± 
s.e.m.; n=6 per group; *p<0.05 by ANOVA with post-hoc Bonferroni test. (f) Radioactivity 
per 10 mg of tissues from mice treated with vehicle, Norepinephrine (NE) or 12,13-
diHOME and then given a bolus of radiolabeled glucose. Tissues were measured by 
scintillation counting in liver, gastrocnemius muscle (Gastroc), soleus muscle, heart, 
BAT, sWAT, and epididymal white adipose tissue (eWAT). Data are means ± s.e.m.; n=8 
per group; *p<0.05 12,13-diHOME vs. Vehicle by ANOVA with post-hoc Bonferroni test.  
 
Supplementary Figure 6 
Un-cropped immunoblots shown in this manuscript. 
 
Supplementary Table 1 
Lipid profiling by LC-MS/MS in human plasma after saline or cold challenge. 
 
Supplementary Table 2 
P values for linear model of relationship between each phenotype with BMI as covariate. 
 
Supplementary Table 3 
Primer Sequences.  
 
Supplementary Table 4 
Antibodies. 
 
Supplementary Video 1 
Representative imaging of FFA-SS-Luc uptake in UCP1cre+/-Rosa(stop)Luc+/- injected 
intravenously with luciferin-conjugated fatty acid and 12,13-diHOME or vehicle. Data 
from individual images using sequential one-minute exposures over approximately 50 
minutes was stacked into a movie. The animal on the left is the vehicle treated and the 
mouse on the right is treated with 12,13-diHOME. 
 Supplementary Video 2 
Representative imaging of FFA-SS-Luc uptake in CAG-Luc+/+ brown adipocyte cells 
treated with 12,13-diHOME or vehicle and then incubate with luciferin-conjugated fatty 
acid. Data from individual images using sequential 30 second exposures over 
approximately 50 minutes was stacked into a movie. The well on the left is vehicle 
treated and the well on the right is treated with 12,13-diHOME. 
 
0 
0.5 
1 
1.5 
2 
2.5 
3 
-3 -1 1 3 
-lo
g 1
0(
p)
  
log2(Fold change cold vs. saline) 
 
a b 
Lynes Figure 1 
R=0.633 
p=0.0047 
12,13-diHOME 
c 
0 
0.5 
1 
1.5 
2 
2.5 
15 35 55 75 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
BMI (kg/m²) 
0 
0.5 
1 
1.5 
2 
2.5 
0 10 20 30 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
HOMA-IR 
0 
0.5 
1 
1.5 
2 
2.5 
0 1 2 3 4 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
Triglycerides (mmol/l) 
0 
0.5 
1 
1.5 
2 
2.5 
0.1 1 10 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
ALAT (µkat/l) 
R=-0.308 
p=0.0219 
R=-0.531 
p=3x10-5 
R=-0.428 
p=0.0011 
d e f 
g h i 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
Saline Cold 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
0 50 100 150 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
BAT activity (mL x mean SUV [g/mL]) 
Cold 
Saline 
0 
0.5 
1 
1.5 
2 
2.5 
0 2 4 6 8 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
LDL-Cholesterol  (mmol/l) 
0 
0.5 
1 
1.5 
2 
2.5 
0 1 2 3 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
HDL-Cholesterol  (mmol/l) 
R=-0.102 
p=0.46 
R=-0.348 
p=0.0011 
R=0.129 
p=0.3493 
p=0.002716 
d 
Lynes Figure 2 
a 
g 
e 
b 
CO2H 
Linoleic Acid 
CO2H 
O 
CO2H 
HO    OH 
12,13-epOME 
12,13-diHOME 
CO2H 
O 
CO2H 
HO    OH 
9,10-epOME 
9,10-diHOME 
CYP450 
sEH 
(Ephx1-4) 
0 
5 
10 
15 
20 
25 
30 
35 
Control 1 hour 
cold 
30 min 
NE 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
** 
0 
5 
10 
15 
20 
25 
Male Female 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
Thermoneutral 
7 day cold 
* p=0.34 
c 
h 
0 
1 
2 
3 
4 
5 
6 
Male 2 days Female 11 days 
12
,1
3-
di
H
O
M
E
 (n
m
/m
g 
pr
ot
ei
n)
 
 
WT Thermoneutral WT Cold 
Myf5   BMPr1a   Thermoneutral Myf5   BMPr1a   Cold 
* * * 
0 
10 
20 
30 
40 
50 
60 
70 
BAT sWAT 
12
,1
3-
di
H
O
M
E
 (n
m
ol
/g
 ti
ss
ue
 
w
ei
gh
t) 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
Ephx1 Ephx2 
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
 Control 
1 hour cold 
* 
0 
1 
2 
3 
4 
5 
6 
R
el
at
iv
e 
E
ph
x1
 e
xp
re
ss
io
n 
Thermoneutral 
Cold * 
0 
0.5 
1 
1.5 
2 
2.5 
3 
R
el
at
iv
e 
E
ph
x2
 e
xp
re
ss
io
n 
Thermoneutral 
Cold f 
BAT        sWAT              eWAT BAT        sWAT              eWAT 
* 7 day cold 7 day cold 
* 
cre f/f cre f/f 
a b 
34 
34.5 
35 
35.5 
36 
36.5 
37 
37.5 
38 
0 15 30 45 60 75 90 
B
od
y 
Te
m
pe
ra
tu
re
 (°
C
) 
Time at 4°C (minutes) 
Vehicle 
12,13-epOME 
12,13-diHOME 
* 
* 
* 
h 
0 
10 
20 
30 
40 
50 
60 
S
er
um
 T
rig
ly
ce
rid
es
 (m
g/
dl
) 
Control 
12,13-diHOME 
* 
0 
100000 
200000 
300000 
400000 
500000 
VO2 VCO2 
 T
ot
al
 V
ol
um
e 
(m
L/
m
ou
se
) 
Cold 
Cold + 12,13-diHOME c * 
* 
0 
10000 
20000 
30000 
40000 
50000 
60000 
70000 
80000 
0 15 30 45 60 75 90 
Lu
m
in
es
ce
nc
e 
(p
ho
to
ns
/s
ec
) 
Minutes after injection 
Vehicle 
12,13-diHOME 
0 
20 
40 
60 
80 
100 
120 
140 
160 
To
ta
l L
um
in
es
ce
nc
e 
(A
rb
itr
ar
y 
U
ni
ts
) 
Vehicle 
12,13-diHOME 
* i 
0.7 
0.72 
0.74 
0.76 
0.78 
0.8 
R
es
pi
ra
to
ry
 E
xc
ha
ng
e 
R
at
io
 
Cold 
Cold+12,13-diHOME 
* 
Lynes Figure 3 
e d 
Vehicle 
12,13-
diHOME 
f 0 
5000 
10000 
15000 
20000 
25000 
Liver Gastroc Soleus Heart BAT sWAT eWAT 
3H
 tr
ig
ly
ce
rid
e-
ra
di
oa
ct
iv
ity
  (
c.
p.
m
. p
er
 1
0 
m
g 
or
ga
n)
 
Vehicle 
12,13-diHOME 
* 
* 
0.0E+00 
5.0E+04 
1.0E+05 
1.5E+05 
2.0E+05 
Liver Gastroc. Soleus Heart BAT sWAT eWAT 3H
 F
FA
-r
ad
io
ac
tiv
ity
 (c
.p
.m
. p
er
 1
0 
m
g 
or
ga
n)
 
Vehicle 
NE 
12,13-diHOME 
0 200 
T0 T10 T55 
Luminescence 
Vehicle 
12,13-
diHOME Vehicle 
12,13-
diHOME 
g 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
1.6 
1.8 
Av
er
ag
e 
FA
AT
P
1 
ol
ig
o 
D
en
si
ty
 (A
.U
.) 
 
Control 
Insulin 
12,13-diHOME 
a 
f 
b d 
e * 
C
TR
L 
In
su
lin
 
12
,1
3-
di
H
O
M
E
 
C
TR
L 
In
su
lin
 
12
,1
3-
di
H
O
M
E
 
 
Cytosol     Membrane 
FATP1 130 kDa 
63 kDa 
Tubulin 
Cadherin 
mono 
oligo 
1 
1.1 
1.2 
1.3 
1.4 
1.5 
1.6 
1.7 
1.8 
1.9 
2 
0 10 20 30 40 50 
R
el
at
iv
e 
Lu
m
in
es
ce
nc
e 
(A
rb
itr
ar
y 
U
ni
ts
) 
Time (minutes) 
Vehicle 
12,13-diHOME 
* 
h 
Cold/ 
Norepinephrine Ephx1/2 
transcription 
Lipolysis 
& Ephx1/2 
activity 
12,13-diHOME 
Brown adipocyte 
Fatty acid 
uptake 
CD36c 
FATP1c 
* 
0 
500 
1000 
1500 
B
as
al
 R
es
ira
tio
n 
(p
M
ol
es
/m
in
) 
Vehicle 
12,13-diHOME * 
Lynes Figure 4 
CD36 
CD36m 
FATP1m 
Acute 
Chronic 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
14
C
 p
al
m
iti
c 
ac
id
 u
pt
ak
e 
 
nm
ol
/h
r/m
g 
pr
ot
ei
n 
 
Vehicle 
12,13-diHOME 
0 
0.0005 
0.001 
0.0015 
0.002 
14
C
 p
al
m
iti
c 
ac
id
 o
xi
da
tio
n 
nm
ol
/h
r/m
g 
pr
ot
ei
n 
 
 
Vehicle 
12,13-diHOME 
p=0.13 
c 
0 
0.5 
1 
1.5 
2 
2.5 
Av
er
ag
e 
C
D
36
 lo
w
 D
en
si
ty
 (A
.U
.) 
Control 
Insulin 
12,13-diHOME 
* g 
low 
high 
a 
Lynes Supplementary Figure 1 
Cyclooxygenase 
Lipoxygenase 
Cyp450 oxidase 
Non-enzymatic 
b 
39	  
24	  
25	   An)-­‐inﬂammatory	  
Pro-­‐inﬂammatory	  
Unknown	  
Inﬂammatory	  eﬀect	  
EPA (20:5 ω
-3) 
ETA (20:3 ω-6) 
D
H
A 
(2
2:
6 
ω
-3
) 
ETA (20:3 ω-6) 
AA (20:4 ω
-6) 
A
A (20:4 ω
-6) 
EPA (20:5 ω
-3) 
AA (20:
4 ω-6) 
ETA (20:3 ω-6) 
9-HOTrE 12,13-diHOME 14(15)-EET 
 Saline   Cold  Saline  Cold   Saline   Cold 
Se
ru
m
	  1
2,
13
-­‐C
on
ce
nt
ra
)o
n	  
(A
.U
.) 
Lynes Supplementary Figure 2 
0 
0.5 
1 
1.5 
2 
2.5 
0 100 200 300 400 500 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
FPI (pmol/l) 
Male 
Female 
0 
0.5 
1 
1.5 
2 
2.5 
0 50 100 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
Leptin (ng/mL) 
Male 
Female 
0 
0.5 
1 
1.5 
2 
2.5 
0.1 1 10 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
ASAT (µkat/l)  
Male 
Female 
0 
0.5 
1 
1.5 
2 
2.5 
0 1 2 3 4 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
gGT (µkat/l) 
Male 
Female 
0 
0.5 
1 
1.5 
2 
2.5 
4 9 14 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
FPG (mmol/l) 
Male 
Female 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
Lean Overweight Obese 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
* 
a 
0 
0.5 
1 
1.5 
2 
2.5 
0 5 10 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
Total Cholesterol (mmol/l) 
Male 
Female 
0 
0.5 
1 
1.5 
2 
2.5 
20 40 60 80 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
Age (years) 
Male 
Female 
0 
0.5 
1 
1.5 
2 
2.5 
4 5 6 7 8 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
HbA1c (%) 
Male 
Female 
0 
0.5 
1 
1.5 
2 
2.5 
0 10 20 30 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
CrP (mg/l) 
Male 
Female 
0	  
0.2	  
0.4	  
0.6	  
0.8	  
1	  
1.2	  
1.4	  
1.6	  
1.8	  
Lean	   Overweight	   Obese	  
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 
 
Male	  
Female	  
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
Lean Overweight Obese 
12
,1
3-
di
H
O
M
E
 (p
m
ol
/m
L)
 NGT 
T2D 
* 
b c 
d e f 
g h i 
j k l 
R=-0.327 
p=0.0148 
R=0.096 
p=0.4833 
R=-0.242 
p=0.0753 
R=-0.24 
p=0.0774 
R=-0.263 
p=0.0518 
R=-0.422 
p=0.0013 
R=-0.282 
p=0.0328 
R=-0.135 
p=0.3254 
R=-0.276 
p=0.0414 
Lynes Supplementary Figure 3 
0 
1 
2 
3 
4 
12
,1
3-
di
H
O
M
E
 (n
m
/m
g 
pr
ot
ei
n)
 
0 
20 
40 
60 
80 
100 
Male 2 days Female 11 
days 
S
er
um
 1
2,
13
-d
iH
O
M
E
 
(p
m
ol
/m
L)
 
WT Thermoneutral 
WT Cold 
Myf5   BMPr1a   Thermoneutral 
Myf5   BMPr1a   Cold 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
Male 2 days Female 11 
days 
sW
AT
 1
2,
13
-d
iH
O
M
E
 
C
on
ce
nt
ra
tio
n 
(n
m
/m
g 
pr
ot
ei
n)
 WT Thermoneutral 
WT Cold 
Myf5   BMPr1a   Thermoneutral 
Myf5   BMPr1a   Cold 
0 
0.5 
1 
1.5 
2 
2.5 
BAT sWAT 
R
el
at
iv
e 
E
ph
x2
 e
xp
re
ss
io
n 
Control 
CL 316,243 
0 
0.5 
1 
1.5 
2 
2.5 
3 
BAT sWAT 
R
el
at
iv
e 
E
ph
x1
 e
xp
re
ss
io
n 
Control 
CL 316,243 
g * 
* 
b 
c 
-2 
-1 
0 
1 
2 
3 
4 
5 
E
ph
x1
 
E
ph
x2
 
C
yp
2b
10
 
C
yp
2u
1 
C
yp
2r
1 
C
yp
1a
1 
C
yp
51
 
C
yp
1b
1 
C
yp
4b
1 
C
yp
2d
22
 
C
yp
2b
13
 
C
yp
4f
16
 
C
yp
20
a1
 
C
yp
4f
17
 
C
yp
39
a1
 
C
yp
2j
6 
C
yp
27
a1
 
C
yp
4f
13
 
C
yp
4v
3 
C
yp
2f
2 
C
yp
2j
9 
C
yp
26
b1
 
C
yp
2e
1 L
og
2F
C
(C
ol
d 
vs
. C
on
tro
l) Hao 2d 
Marcher 3d 
Hao 4d 
Rosell 10d 
a 
Lynes Supplementary Figure 4 
p=0.06 
** 
0 
1 
2 
3 
4 
Ephx1 Ephx2 Ephx3 Ephx4 Ephx1 Ephx2 Ephx3 Ephx4 Ephx1 Ephx2 Ephx3 Ephx4 Ephx1 Ephx2 Ephx3 Ephx4 
BAT sWAT Kidney Liver R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
 
Thermoneutral 
7 day cold 
d 
f 
e 
* 
* 
* * 
* 
* * 
* 
*** 
cre 
cre f/f 
f/f 
cre 
cre f/f 
f/f 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
12
,1
3-
di
H
O
M
E
 (p
g/
m
g 
pr
ot
ei
n)
  
* 
h * 
Lynes Supplementary Figure 5 
a b c 
0 
100 
200 
300 
400 
500 
600 
P
ul
se
 (B
P
M
) 
Vehicle 
12,13-diHOME 
0 
20 
40 
60 
80 
100 
120 
140 
S
ys
to
lic
 p
re
ss
ur
e 
(m
m
H
g)
 
Vehicle 
12,13-diHOME 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
D
ia
st
ol
ic
 p
re
ss
ur
e 
(m
m
H
g)
 
Vehicle 
12,13-diHOME 
0 
1,000 
2,000 
3,000 
4,000 
5,000 
Liver Gastroc Soleus Heart BAT sWAT eWAT 
14
C
-r
ad
io
ac
tiv
ity
 
(c
.p
.m
. p
er
 1
0 
m
g 
tis
su
e)
 Vehicle 
NE 
12,13-diHOME 
0 
50 
100 
150 
200 
250 
0 60 120 180 240 
S
er
um
 T
rig
ly
ce
rid
es
 (m
g/
dl
) 
Time (min) 
Vehicle 
12,13-diHOME 
* 
* 
f 
e 
Lynes Supplementary Figure 6 
d * 
0 
100 
200 
300 
400 
500 
600 
0 15 30 45 60 75 90 105 120 
B
lo
od
 g
lu
co
se
 (m
g/
dl
) 
Time (min) 
Vehicle 
12,13-diHOME 
a b 
0 
0.5 
1 
1.5 
2 
2.5 
3 
S
er
um
 F
FA
 (m
E
q/
L)
 
Vehicle 
12,13-diHOME 
c 
0 
10 
20 
30 
40 
50 
60 
0 1 2 3 4 5 6 7 
B
od
y 
w
ei
gh
t (
g)
 
Days of treatment 
Vehicle (+3.2%) 
12,13-diHOME (+3.7%) 
p=0.227 
0 
0.5 
1 
1.5 
2 
2.5 
UCP1 LPL UCP1 LPL 
BAT sWAT 
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
 Vehicle 
12,13-diHOME 
Lynes Supplementary Figure 7 
C
on
tro
l 
In
su
lin
 
12
,1
3-
di
H
O
M
E
 
C
on
tro
l 
In
su
lin
 
12
,1
3-
di
H
O
M
E
 
 
Cytosol Membrane 
FATP1 
CD36 
Tubulin 
Cadherin 
Subject 341-­‐01 341-­‐02 341-­‐03 341-­‐04 341-­‐05 341-­‐06 341-­‐07 341-­‐08 341-­‐09 341-­‐01 341-­‐02 341-­‐03 341-­‐04 341-­‐05 341-­‐06 341-­‐07 341-­‐08 341-­‐09
Treatment Cold Cold Cold Cold Cold Cold Cold Cold Cold Saline Saline Saline Saline Saline Saline Saline Saline Saline
Code 341-­‐01-­‐C 341-­‐02-­‐C 341-­‐03-­‐C 341-­‐04-­‐C 341-­‐05-­‐C 341-­‐06-­‐C 341-­‐07-­‐C 341-­‐08-­‐C 341-­‐09-­‐C 341-­‐01-­‐S 341-­‐02-­‐S 341-­‐03-­‐S 341-­‐04-­‐S 341-­‐05-­‐S 341-­‐06-­‐S 341-­‐07-­‐S 341-­‐08-­‐S 341-­‐09-­‐S
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0.8820752 0.13772466 0.30110357 0.40821832 0.46119151 0.38578526 0.53432263 0.11439154 1.66230684 0.22070346 0.13464997 0.67824337 0.33963432 0.12871609 0.16220992 0.06446726 0.36655777 0.6221771
0.84687575 0.23180595 0.08310963 0.37735672 0.44132719 0.37386546 0.38222553 0.13517607 1.23434785 0.14931878 0.16398264 0.44110481 0.29814292 0.11087036 0.14897919 0.03521053 0.18031766 0.47868483
0.17697993 0.03389002 0.09420009 0.10592884 0.0370685 0.03113476 0.10456824 0.03061817 0.09664619 0.05040424 0.03213139 0.03560318 0.05618638 0.0291903 0.01039693 0.02553466 0.04993029 0.05675979
0 0.00212058 0.08444003 0.05244116 0.03325706 0.02123659 0.08367766 0.08187226 0.01455282 0.07389398 0.03267962 0.31266571 0.09382568 0.00671887 0.01854387 0.0355627 0.04223872 0.12527225
3.91943541 1.22345046 0.67334838 1.31061089 1.86791051 1.0102823 1.96652953 0.94789946 5.64421903 1.59699636 0.42535328 3.18619718 1.30629673 0.52118429 0.54076628 0.56493647 0.95049219 4.60993797
5.12097498 1.12833588 0.82558584 1.75618796 2.63683682 1.34057854 2.45533991 1.16158199 8.28243273 1.62602974 0.47028437 3.37096622 2.23948275 0.54787381 0.62625744 0.67280668 1.20385351 2.7311558
2.20215408 0.74125195 0.31476495 0.27484368 0.53126437 0.37912148 0.71423327 0.49946771 1.97850056 0.40949975 0.28451051 1.80132934 0.83020776 0.21822925 0.12019162 0.05716339 0.50686715 0.24733913
1.87320275 0.79379427 0.41317053 0.4362924 0.57413432 0.47966661 0.80479263 0.54021352 2.49837296 0.4873635 0.46113654 1.67584874 0.91390139 0.25161919 0.24222062 0.0865 0.60470406 1.58567437
3.3272534 0.90768129 0.99019041 0.57254189 0.87079847 0.56103895 0.98862293 1.19871882 1.18568809 0.49795281 1.162309 0.52972917 0.8081577 0.41988789 0.24595267 0.35718634 1.2049586 0.77173535
1.46875726 0.71652283 0.73638901 0.77912647 0.7267959 0.44177781 0.87098188 1.03721686 0.84714557 0.4575017 0.53594509 0.36370236 0.67222662 0.28907866 0.19869644 0.23709389 0.48616595 0.6838185
0.03482791 0.0226062 0.01393433 0.00128854 0.00452034 0.04189755 0.01187777 0 0.01691096 0 0.01633175 0.03412209 0.04322722 0.00749832 0 0 0 0.00599058
0.03995867 0 0.02781801 0.00839931 0.00649814 0.01278576 0.02861311 0.03783117 0.01252254 0.00648206 0.07548249 0.00512205 0.0336037 0.00278939 0.0487373 0.03779358 0.01255589 0.01465769
0.03797506 0 0.00669321 0.00331692 0 0 0.00649222 0 0.0059629 0.01480579 0 0 0.02927001 0 0.01122213 0.03477062 0 0.00410264
0.01443379 0.0089581 0.00591013 0.00831136 0 0.03951262 0.03103896 0 0 0.02850702 0.02693501 0.01779496 0.00432579 0 0.00423175 0.02931917 0.00846928 0.00333205
0.02045306 0 0 0.00310293 0 0.01149639 0.00475933 0 0.0039127 0 0.01437334 0 0.01895096 0 0 0 0.01279124 0.00417701
0.01577257 0.02781498 0 0 0.00814537 0.02094913 0 0.01078564 0 0 0 0 0.0086514 0 0.00862009 0.02288272 0.0084697 0
0.01796359 0.00426954 0 0.00675241 0 0.0153798 0.00570874 0.03426826 0 0 0.04323442 0 0 0.00548504 0.00458438 0 0 0.0038982
0 0 0 0 0 0 0 0 0.00426522 0 0 0 0 0.00354795 0 0 0 0
0.02118569 0.05183913 0 0.00918021 0 0.00997707 0.024636 0.03407762 0.04587191 0.00648871 0 0 0.00432557 0 0.01722086 0 0.00919167 0
0.01578896 0.034617 0.04466404 0 0.02181022 0 0.00640353 0.05752618 0.05576792 0.01881642 0.04062346 0.00531622 0.00168112 0.00278909 0.02441701 0.02822197 0 0.00961029
0 0.05018695 0.00929148 0.01584103 0 0.04858976 0.02459868 0.00464922 0 0.0345319 0.10462385 0.02023739 0 0.00957971 0.03720013 0.00530879 0.01693959 0.00449927
0.00643152 0.00161645 0 0 0.00800458 0.01278646 0.03103985 0.03556599 0.0229632 0.01482362 0.05393147 0.01920405 0.00432579 0.00154816 0 0 0.03802619 0.00381695
0.07191695 0.04967329 0.05489717 0.02421615 0.0182332 0.03551278 0.06858253 0.13475127 0.04767125 0.08072385 0.11617988 0.01358925 0.04751897 0.02529085 0.02811637 0.03147345 0.01461535 0.03664841
0.1665798 0.08207757 0.04170098 0.03502899 0.04040702 0.14849331 0.27205378 0.11740046 0.04314802 0.04076668 0.24696941 0.02658043 0.08995519 0.02911897 0.0248371 0.92245723 0.00872025 0.05640258
0.14201379 0.15667264 0.11004592 0.0491466 0.02794356 0.20771158 0.24605791 0.23871839 0.20932031 0.19722658 0.31201862 0.08347809 0.04301536 0.02577249 0.05942672 0.08752551 0.12765647 0.09497188
0.05374696 0.13715509 0.02223985 0.01021937 0.00608212 0.01917904 0.01598946 0.00464922 0.08172544 0.06587482 0.07824381 0 0 0.00294681 0.02229653 0.00535926 0.00768525 0.01374217
0.15478346 0.11454226 0.01821948 0.04501689 0.02968725 0.10309355 0.06475798 0.18665149 0.15898088 0.11062228 0.09429788 0.01316201 0.29821177 0.07710361 0.07707103 0.70649298 0.08582017 0.04986108
0.04581254 0.00849749 0.03481581 0.01900474 0 0.02185598 0.01627169 0.01175279 0.0177593 0.01206397 0.02780117 0.00960223 0.00397036 0 0.03448142 0 0.01086333 0.00711744
0 0.11589514 0.0831147 0.01190338 0.02470268 0.0416021 0 0.07104636 0 0.04626907 0.20026577 0.06238974 0.12378804 0.02452737 0.04716968 0.01727634 0.24170241 0.02718897
0.02976464 0.03681365 0.00921048 0.01917963 0 0.07672836 0 0.10356622 0.07710787 0.07537659 0.19277452 0.03436163 0.03017551 0.04201908 0.05321102 0 0 0.01730326
0.00643083 0.04239607 0 0 0 0.0055111 0 0 0.00913759 0.03682737 0.02874102 0.00531599 0.00432558 0.00393721 0 0.03985586 0 0.01199032
0.0336904 0.04170806 0 0.01531632 0.00899042 0.00850767 0.00991709 0.03182722 0.00539254 0 0.05428681 0.01801625 0.07517357 0 0 0.06338788 0.03307261 0.01220137
0.01327579 0.03598697 0 0 0.00501076 0.00775905 0 0.00218906 0.02369955 0.01036466 0 0 0.0087393 0.00843015 0 0 0.0038656 0
0.01327579 0.00520328 0 0 0.00501076 0.00775905 0 0.01285761 0 0 0 0.00249753 0.00708181 0 0 0 0 0
0.04434704 0.01750288 0.0114727 0.00961816 0 0.01576784 0 0 0.00801009 0.01258684 0 0.00082286 0 0 0.00878691 0.00395142 0 0.00109043
0 0 0 0 0 0 0 0 0.0049252 0 0.00752271 0 0 0 0.00570484 0 0 0
0.01265234 0 0.01071905 0 0 0 0 0 0 0 0.01362103 0 0 0 0 0.00452613 0.00386563 0.00766148
0.13086115 0.03094994 0 0 0 0 0.0633934 0.14383265 0 0 0 0.02119478 0 0.08715058 0 0 0.01418545 0.008345
0.01104692 0.03963729 0.00923092 0.00331692 0.00223335 0.02095718 0.00401189 0.04854841 0.00596288 0.03129745 0.03253428 0 0 0.00787485 0 0.1217398 0 0.00435603
0 0.00520821 0 0.00371737 0 0.03399313 0.02354642 0 0 0 0 0.00512305 0.00432564 0 0 0 0 0.00435581
0.0222041 0 0.00925261 0.00780255 0.00606823 0.02094808 0.02561428 0 0.01192581 0 0.02693615 0 0.0231951 0.00546205 0.02171119 0.02822318 0.01547035 0.00416748
0.01626243 0 0 0 0 0.02094824 0.03876309 0 0.02739624 0 0 0.00450554 0.01895612 0 0 0 0 0.00416525
0.0157719 0.02205848 0.03543268 0 0.00904059 0 0 0.03117691 0 0 0.01484626 0.01491797 0.00432579 0.00812764 0.01425676 0.00531269 0 0
0 0 0.01846295 0 0 0 0 0.00881858 0 0 0.05170875 0 0 0.00278911 0 0.02888005 0 0.00434652
0.02699201 0 0.00923194 0.00331681 0.00608207 0 0.01280712 0.04021322 0.00596318 0 0.04690383 0 0.06286332 0.00920093 0 0.0884625 0.0311973 0
0 0.01402686 0.00923179 0.00521808 0.00452035 0.00787255 0.00946175 0.03556135 0 0 0.05051611 0.00669153 0.00222847 0.00932429 0.00860048 0.07601718 0.00846921 0.00600437
0 0.00519654 0.03543118 0.01199923 0 0.03154359 0.00476209 0.01793754 0.0229103 0.06892118 0.05129034 0.00888749 0 0.01044571 0 0.0244436 0.01040728 0.01345364
0 0.00519654 0.00477116 0 0 0 0 0.01286167 0 0.06750689 0 0 0 0.00934214 0 0.02291146 0 0
0 0.00169609 0 0 0 0 0 0.04020443 0 0.01480579 0 0.02451986 0.00419905 0.00492333 0 0.02291011 0.01471839 0
0.03237649 0.03311641 0.00162726 0 0.00263481 0.0154526 0 0.01966326 0.00613352 0.00180509 0.00403581 0.00601951 0.00436398 0.02118443 0.00148337 0.04024763 0.00934356 0.00283751
0.05110797 0 0.00299722 0.00310629 0 0.00786371 0.00534238 0.00539098 0.00955062 0 0.00382797 0.0020889 0.00276077 0 0.00328019 0.02318241 0 0.0032589
0.03969985 0.01253619 0.00335969 0 0 0 0 0 0.0033298 0.00564954 0 0.00862614 0.00766044 0.00323691 0 0 0 0.00104566
0.00214888 0.00283358 0.00318569 0.0060449 0.00517021 0.00518695 0.01116179 0 0.00194575 0.01881837 0.02066103 0 0 0.02335869 0 0.01220011 0 0.001208
0 0 0.00368083 0 0 0.00353299 0.01212309 0 0.01668138 0.018012 0.0028776 0.00166392 0 0.00866126 0.00045731 0.00204585 0.0031371 0.00216842
0.00476807 0.01285741 0 0.00697658 0 0 0.00825804 0.00278101 0.00666099 0.00853768 0.00553044 0 0.00455911 0.0030836 0 0.02082041 0 0.00262427
0.04834704 0.00998238 0.00162723 0.00546839 0.00189556 0.00537476 0.01599245 0.00789616 0.00666484 0.0107805 0.01515891 0 0.00227298 0 0.00244245 0.01225892 0.00175041 0
0.03029478 0.00848361 0.00318834 0.00894722 0.00526992 0.00342366 0.02811518 0.00521461 0.01039009 0 0.0056297 0.00713767 0.00867168 0.00962842 0 0.01013146 0.00171746 0.00444059
0.0047708 0.02794274 0 0.00681215 0 0.00518683 0.01599794 0.00821993 0.02295678 0.00281416 0.02229943 0 0.00658218 0.00961785 0.00618589 0.03967214 0.00548882 0.00763858
0.0329723 0.00848361 0.00318834 0.00894392 0.00526964 0.00247984 0.02182173 0.00432122 0.00780757 0 0.0056297 0.00601947 0.00746147 0.00769415 0 0.00362795 0.00174637 0.00652314
0.01220498 0.01362698 0.00184412 0.00970778 0 0.00353314 0.01108831 0 0.01640537 0 0.01698265 0.00206176 0.00435662 0 0.00444197 0 0.00175036 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0.00258433 0.00318108 0.00310627 0.0029401 0 0 0.00666235 0 0 0.00562975 0 0.0013633 0.00962882 0.00407104 0.006565 0 0.00241397
0.15578249 0.01980041 0.01436194 0.00537447 0.04811491 0.00586518 0.17335966 0.00958853 0.0562911 0 0.01535797 0 0.02116264 0.10979916 0.00296675 0.42155733 0.02836876 0.00853881
0 0.00848333 0 0 0.00294026 0 0.00316439 0.01108041 0 0 0 0.00601946 0 0.0032766 0 0.01927389 0.00524866 0.00114938
0 0 0.00162726 0.00402614 0 0.00600204 0.0031643 0 0 0.00281505 0 0.00206177 0 0 0 0 0 0.00340826
0 0 0 0 0.00263174 0 0.00311709 0.0020744 0.00286939 0 0 0 0 0.00814485 0 0 0 0
0 0 0 0 0 0 0.0069399 0.00207584 0 0.00274752 0.00675513 0 0 0.0032766 0.00144572 0 0 0.00761101
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0.00603215 0 0 0 0.00209026 0 0 0 0 0 0 0 0 0 0 0.00319376 0 0
0 0.00374594 0 0.00310614 0 0 0.00251544 0 0 0 0 0 0 0 0.00148337 0 0.00206371 0
0 0.0028265 0.05960986 0.00379564 0 0 0 0 0 0 0.07473816 0.00860168 0.05117547 0 0 0 0 0.06129607
0.00603215 0 0 0 0 0.00518699 0 0 0 0 0 0 0 0 0 0 0 0
0 0.01622295 0.00481326 0.00402611 0.00558118 0 0 0.00562756 0 0 0.00470715 0 0.00240464 0.00327344 0 0.02094648 0 0.00253709
0.01048766 0.01085063 0.00318108 0.00703436 0.00153868 0.00336492 0.0054352 0.0081337 0 0.00074161 0.01062494 0.00650242 0.00892767 0.00962882 0 0 0.00116949 0
0.00477386 0.00515664 0 0.01023857 0 0 0 0.00262997 0 0.00514772 0 0.00470749 0 0.00327646 0 0.00428663 0.0024919 0
0.00880852 0.00284002 0 0 0.01155394 0.01012046 0.01599827 0.00521788 0 0 0 0.00465665 0.00276347 0.01978713 0.00296673 0.02575126 0.00350073 0.00374253
0.0034526 0.00266656 0.01071895 0.01428401 0.06458497 0.00775866 0.04597991 0 0.0105659 0.03623538 0.02660184 0.00935528 0.00465124 0 0.02635985 0.00644169 0 0.00190449
0.01894492 0.02246293 0 0.00211861 0.00193267 0 0.00602079 0.01210574 0.01377357 0.02176487 0.02713225 0.02691133 0.0098876 0.03365783 0.01879593 0.00584746 0.02920653 0.00761823
0.13832154 0.01530025 0.02961696 0.03621561 0.0679621 0.14266708 0.18449487 0.03568834 0.13386157 0.16961684 0.11246387 0.04509038 0.02393381 0.02095105 0.17118215 0.01979974 0.05983042 0.01741919
0.25314244 0.2851802 0.08407026 0.06673701 0.08865614 0.20891383 0.14621531 0.08789911 0.17444377 0.18282615 0.17465069 0.15817538 0.0427578 0.20256671 0.22901717 0.04850597 0.10086025 0.07283636
0 0.02911327 0.02872587 0.00412028 0 0.02094915 0 0.0354841 0.03483118 0.11552983 0 0.00532609 0 0 0 0 0.04721793 0.01008503
0.07079045 0.07777401 0.04262773 0.00667031 0 0.05226377 0 0 0.13868969 0.02130126 0.02693501 0 0.03359437 0 0.03115187 0.07847393 0.00846921 0.00417684
0.12283663 0.1338614 0.03874481 0.0717968 0.07878727 0.14105611 0.04945661 0.41635866 0.32535658 0.32187915 0.91450788 0.05276736 0.33742994 0.04114536 0.0662108 0.36815073 0.26520039 0.02333672
0.19657519 0.0148816 0.09533832 0.01938806 0.09466181 0.15260692 0.1294652 0.05666532 0.10466447 0.21054674 0.16100974 0.03036406 0.04923989 0.17368477 0.18713177 0.0622569 0.06385036 0.10421156
0 0 0.00162726 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0.03392007 0.01693021 0.00315956 0.01354647 0.03424425 0.02280314 0.00578632 0.01711792 0.01633068 0.04838009 0.01499458 0.00112402 0.02377063 0.01067354 0.00773433 0.00431489 0.00253698
0 0 0.00235668 0.00310616 0.00263493 0.00353314 0 0.00655911 0.00801773 0.00654388 0 0.00157938 0 0.00584882 0 0.04531966 0 0
0.01286271 0.02285245 0.00923179 0.03868014 0.02395912 0.07868379 0.06323881 0.02416028 0.02974028 0.09532808 0.05031429 0.02126462 0.09187375 0.02698304 0 0.04328249 0 0.02259983
	  
Precursors Docosanoids 0.44457102 0.15078243 0.24057397 0.06849294 0.12523814 0.29840486 0.32919493 0.39769005 0.19809762 0.38108731 0.46634915 0.09580794 0.16949095 0.33154691 0.23614217 0.46277348 0.14919596 0.1644754
Eicosanoids 3.16430801 2.065358 1.35995176 1.21503573 1.24483445 1.68986643 2.3451846 2.42629028 2.37806793 1.94569993 3.00003896 0.95737846 1.52644377 0.91967462 1.04405385 2.54916794 1.32541319 1.11153383
Octadecanoids 9.30854111 2.84614814 2.19653918 2.17518185 2.91578437 2.21061251 3.52876524 2.51858581 8.65586249 1.81524255 2.23872005 5.16185862 3.24623048 1.15851309 0.92995095 0.62606218 2.91333553 3.76237058
Inflammatory Anti-­‐inflammatory 7.77025571 3.0421212 2.15121665 2.91924816 3.49962083 2.8753129 4.31060166 3.40145576 8.8932373 3.45884187 3.29394784 4.5228972 3.12171484 1.61600558 1.77581688 1.94358209 2.35996116 6.20284882
Pro-­‐inflammatory 13.9253286 4.20927298 3.12483579 3.62302841 5.20165711 3.60107252 6.17272985 4.04290409 16.0258439 3.71776977 3.23782076 8.5178867 5.38231456 1.70707805 1.53655225 2.42593049 4.11130551 6.26715966
Enzymatic COX 0.39802421 0.14483448 0.10184432 0.06980047 0.07050444 0.05878489 0.2740405 0.11924542 0.13405346 0.08429828 0.18105493 0.0779488 0.12147372 0.20968652 0.01914308 0.59547977 0.06969611 0.09098157
CYP450 14.2303109 4.34536852 3.26474616 3.66621017 5.38027009 3.97172755 6.26394498 4.06039291 16.3664167 4.14311064 3.46957095 8.41098624 5.30341928 2.01566371 2.131215 1.51813757 4.27567713 6.27617438
LOX 8.2450646 2.92829671 2.30022923 3.25252239 3.81652389 2.91246982 4.69918886 3.41448326 10.2797602 3.3016972 3.06819946 5.27858119 3.55813921 1.36076381 1.37873527 2.82287832 2.59977874 6.80387067
13-­‐HOTrE/13-­‐HOTrE(r)
Species
IS-­‐d4-­‐9-­‐HODE
9-­‐oxoODE
13-­‐oxoODE
9-­‐HOTrE
8-­‐HEPE
9-­‐HODE
13-­‐HODE
9(10)-­‐EpOME
12(13)-­‐EpOME
9,10-­‐diHOME
12,13-­‐diHOME
18-­‐HEPE
15-­‐HEPE
12-­‐HEPE
5-­‐HEPE
11-­‐HEPE
16-­‐HETE
15-­‐oxoETE
9-­‐HEPE
14(15)-­‐EET
11(12)-­‐EET
8(9)-­‐EET
5(6)-­‐EET
15-­‐HETE
12-­‐HETE
5-­‐HETE
20-­‐HETE
11-­‐HETE
7-­‐HDHA
17-­‐HETE
18-­‐HETE
9-­‐HETE
8-­‐HETE
all	  trans-­‐LTB4
LTB4
5,6-­‐diHETE
5,15-­‐diHETE
Hepoxilin	  A3
17-­‐HDHA
14-­‐HDHA
LXA4
4-­‐HDHA
8-­‐HDHA
10-­‐HDHA
11-­‐HDHA
13-­‐HDHA
16-­‐HDHA
20-­‐HDHA
19(20)-­‐EpDPE
16(17)-­‐EpDPE
PGE2/PGD2
PGD2
6-­‐keto-­‐PGF1a
LXB4
15-­‐keto-­‐PGF2a
13,14-­‐dihydro-­‐15-­‐keto	  PGE2
13,14-­‐dihydro-­‐15-­‐keto	  PGD2
PGF2a
PGE1/D1
8-­‐iso	  PGF2a
5-­‐iPF2a-­‐VI
Maresin1
PD1
TxB2
15-­‐deoxy-­‐delta12,14-­‐PGD2
19/20-­‐OH	  PGF2a
RvD1
RvD2
LTE4
LTD4
LTC4
PGF1a
15-­‐keto-­‐PGE2
PGD3
PGA2/PGJ2
PGB2
Tetranor-­‐12-­‐HETE
5,6-­‐DiHETrE
8,9-­‐DiHETrE
11,12-­‐DiHETrE
14,15-­‐DiHETrE
5-­‐HETrE
8-­‐HETrE
15-­‐HETrE
19,20-­‐DiHDPA
2.3-­‐dinor-­‐11beta-­‐PGF2a
15-­‐deoxy-­‐delta12,14-­‐PGJ2
TxB3
Covariate p
Age 0.191
FPG 0.507
FPI 0.747
HOMA-­‐IR 0.643
HbA1c 0.48
CrP 0.73
Leptin 0.154
Total.Cholesterol 0.674
HDL.Cholesterol 0.392
LDL.Cholesterol 0.788
Triglycerides 0.0463
ALAT 0.0494
ASAT 0.0274
gGT 0.138
Primer Sequence Gene
ARBPfor TTTGGGCATCACCACGAAAA
ARBPrev GGACACCCTCCAGAAAGCGA
Ephx1for GGAGACCTTACCACTTGAAGATG
Ephx1rev GCCCGGAACCTATCTATCCTCT
Ephx2for ACCACTCATGGATGAAAGCTACA
Ephx2rev TCAGGTAGATTGGCTCCACAG
Ephx3for CAGTGGACTCCGATAGCACG
Ephx3rev TGGGACGACTACAGAGCCG
Ephx4for TCCCTGGTGTACGGCTACTG
Ephx4rev ATCTTAACCCGGAGTCCTTGA
UCP1for AGGCTTCCAGTACCATTAGGT
UCP1rev CTGAGTGAGGCAAAGCTGATTT
LPLfor GCCCAGCAACATTATCCAGT
LPLrev GGTCAGACTTCCTGCTACGC LPL
UCP1
ARBP
Ephx1
Ephx2
Ephx3
Ephx4
Antibody	  List Vendor Catalog	  #
FATP1(ALSVL5,	  m-­‐100) Santa	  Cruz	  Biotechnology sc-­‐25541
Pan-­‐Cadherin(H-­‐300) Santa	  Cruz	  Biotechnology sc-­‐10733
β-­‐Tubulin Cell	  Signaling	  Technology 2146
HRP	  conjugated	  anti	  Rabbit	  IgG Cell	  Signaling	  Technology 7074
Anti-­‐CD36 Santa	  Cruz	  Biotechnology sc-­‐9154
